Form 4: Mineralys Therapeutics Chief Medical Officer Exercises Stock Options

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options for 5,017 shares at a price of $0.54 per share.

Summary

• David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, exercised stock options on December 11, 2024.
• He acquired 5,017 shares of common stock at a price of $0.54 per share.
• This transaction increased his direct ownership of common stock to 146,008 shares.
• The stock options were granted previously and vested over time, with 25% vesting on March 12, 2022, and the remainder vesting monthly over 36 months.
• The exercised options were part of a larger grant that included 5,018 options.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing an executive's stock option exercise, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects the standard practice of executives exercising vested stock options.

Comparison to Industry Standards

• Stock option exercises are a common form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule described is typical, with an initial vesting period followed by monthly vesting over a set period.
• The exercise price of $0.54 is likely based on the company's stock price at the time the options were granted.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Mineralys Therapeutics, MLYS, Chief Medical Officer, equity securities